Treatment of limb synovial sarcoma with metastasis at presentation.

Szczegóły
Abstrakt

Tytuł:: Treatment of limb synovial sarcoma with metastasis at presentation.
Autorzy:: Guo P; Department of Orthopaedics, First People's Hospital of Huzhou, First Affiliated Hospital of Huzhou University, Huzhou.
Zhao R; Department of Orthopaedics, Taizhou Tumor Hospital, Wenling.
Zhou Y; Department of Orthopaedics, Health Community Group of Yuhuan Second People's Hospital, Yuhuan, Zhejiang, China.
Shen Y; Department of Orthopaedics, First People's Hospital of Huzhou, First Affiliated Hospital of Huzhou University, Huzhou.
Źródło:: Medicine [Medicine (Baltimore)] 2020 Jun 05; Vol. 99 (23), pp. e20550.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
MeSH Terms:: Neoplasm Metastasis*
Extremities/*surgery
Sarcoma, Synovial/*mortality
Sarcoma, Synovial/*therapy
Soft Tissue Neoplasms/*mortality
Soft Tissue Neoplasms/*therapy
Adult ; Chemotherapy, Adjuvant ; Female ; Humans ; Male ; Prognosis ; Radiotherapy, Adjuvant ; SEER Program ; Sarcoma, Synovial/pathology ; Soft Tissue Neoplasms/pathology ; Survival Analysis
References:: J Clin Oncol. 2003 Apr 15;21(8):1602-11. (PMID: 12697886)
Med Pediatr Oncol. 1999 Jan;32(1):32-7. (PMID: 9917750)
Am J Surg Pathol. 1999 Mar;23(3):268-75. (PMID: 10078916)
Clin Cancer Res. 2008 Dec 15;14(24):8191-7. (PMID: 19088035)
J Clin Oncol. 2001 Jan 15;19(2):525-34. (PMID: 11208847)
J Clin Oncol. 2004 Oct 15;22(20):4040-50. (PMID: 15364967)
J Clin Oncol. 2000 Nov 15;18(22):3794-803. (PMID: 11078492)
Cytopathology. 2019 Sep;30(5):504-509. (PMID: 31161693)
J Cancer. 2019 Jun 2;10(11):2457-2463. (PMID: 31258751)
Cancer. 2009 Jul 1;115(13):2988-98. (PMID: 19452538)
Sarcoma. 2011;2011:231789. (PMID: 21559258)
Ann Surg. 2007 Jul;246(1):105-13. (PMID: 17592298)
Ann Oncol. 2011 Feb;22(2):458-67. (PMID: 20716627)
J Surg Oncol. 2018 Mar;117(4):788-796. (PMID: 29165811)
Cancer Discov. 2015 Feb;5(2):124-34. (PMID: 25614489)
Ann Oncol. 2005 Mar;16(3):437-44. (PMID: 15653701)
Am J Clin Oncol. 2013 Feb;36(1):83-8. (PMID: 22270107)
Oncol Lett. 2019 Sep;18(3):2179-2191. (PMID: 31404317)
J Clin Oncol. 1994 Nov;12(11):2360-6. (PMID: 7964951)
Cancer Res. 2002 Jan 1;62(1):135-40. (PMID: 11782370)
Cancer. 2012 Aug 1;118(15):3758-65. (PMID: 22180344)
Cancer. 1994 May 15;73(10):2506-11. (PMID: 8174046)
Ann Oncol. 2009 Mar;20(3):425-30. (PMID: 19088169)
Clin Orthop Relat Res. 2018 Mar;476(3):589-598. (PMID: 29529647)
J Pediatr Hematol Oncol. 2005 Apr;27(4):215-8. (PMID: 15838394)
Cancer. 2004 Aug 1;101(3):627-34. (PMID: 15274077)
Cancer. 2009 Aug 1;115(15):3537-47. (PMID: 19514087)
Eur J Cancer. 2017 Jun;78:1-6. (PMID: 28391003)
J Clin Oncol. 2000 May;18(10):2087-94. (PMID: 10811674)
Entry Date(s):: Date Created: 20200606 Date Completed: 20200622 Latest Revision: 20221005
Update Code:: 20240104
PubMed Central ID:: PMC7306353
DOI:: 10.1097/MD.0000000000020550
PMID:: 32502019
: Czasopismo naukowe

Full Text Finder

Limb synovial sarcoma (LSS) patients with metastasis at presentation usually have a very poor prognosis. Little is known about survival prediction and risk factors in these patients owing to the condition's rarity. Thus, this study examined the survival and prognostic variables of metastatic LSS.Clinical data for LSS patients with metastasis at presentation from 1975 to 2016 were obtained from the surveillance, epidemiology, and end results database. The Kaplan-Meier method was used to determine the survival curves. Univariate and multivariate Cox regression analysis were conducted to identify the prognostic predictors.The study enrolled 217 patients. Male predominance was observed in the metastatic LSS group. The median age at diagnosis of this population was 40 years. The subtypes were "not otherwise specified" (49.8%), spindle cell (32.7%), biphasic (17.1%), and epithelioid cell (0.5%). The 3-year overall and cancer-specific survival rates of the entire group were 27.2% and 28.3%, respectively. Tumor size <10 cm, surgery, radiotherapy, and chemotherapy were independent predictors of improved overall and cancer-specific survival in the multivariate analyses.Comprehensive treatment for LSS patients with metastasis at diagnosis is necessary and effective and can prolong survival.

Informacja